The role of rifaximin in irritable bowel syndrome derived from a network meta-analysis of randomized control trials
Objective: Recent randomized control trials (RCTs), have demonstrated the beneficial therapeutic effects of rifaximin for the treatment of the irritable bowel syndrome (IBS). However, in these studies different drug doses have been used and still the optimal therapeutic dose is missing. We aimed to...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Verduci Editore
2020-07-01
|
| Series: | Microbiota in Health and Disease |
| Subjects: | |
| Online Access: | https://www.microbiotajournal.com/wp-content/uploads/sites/7/2020/07/e333.pdf |